ClearPoint Neuro (CLPT) AI Stock Analysis

• Market Cap: $362.64M
• Dividend Yield: N/A
• Average Volume (3M): 272.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: 23.22%
• EPS Growth: 9.54%
• Country: US
• Employees: 115
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Devices
• EPS (TTM): -0.22
• Shares Outstanding: 28,265,001
• 10 Day Avg. Volume: 248,497
• 30 Day Avg. Volume: 272,698
• PEG Ratio: 2.05
• Price to Book (P/B): 18.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -31.73
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 2.98
• Enterprise Value/Gross Profit: 18.43
• Enterprise Value/Ebitda: -5.09
• 1Y Price Target: $27.67
• Price Target Upside: 98.64% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 61 Neutral
• Price Target: $13.50 ▼(-3.09%Downside)

The overall stock score is driven by strong revenue growth and strategic funding initiatives. However, profitability issues and technical indicators reflecting neutral momentum weigh down the score. The company's ability to mitigate operating losses and convert revenue growth into profitability will be key to future improvements.

Positive Factors

Financial Stability

The balance sheet is solid with over $20M of cash and no debt.

Growth Potential

Functional Neuro growth in Q4 was strong at 43% year-over-year.

Partnerships

Current ClearPoint partners with accelerated development pathways cater to a patient population of over 2 million.

Negative Factors

Market Timing

The partner business recently had significant developments that accelerate $100s of millions of revenue opportunities, with 70%+ GMs, to being on the market as early as late 2026.

ClearPoint Neuro Business Overview & Revenue Model

Company Description

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

How the Company Makes Money

ClearPoint Neuro generates revenue primarily through the sale of its ClearPoint Neuro Navigation System and related disposables used during surgical procedures. The company also earns income from service agreements, which may include maintenance and support for their systems. Additionally, ClearPoint Neuro may engage in partnerships or collaborations with other companies, contributing to its earnings through shared ventures or licensing agreements. These partnerships often help expand the reach and application of their technology within the healthcare industry.

ClearPoint Neuro Financial Statement Overview

Summary

ClearPoint Neuro demonstrates positive revenue growth and a solid balance sheet with low leverage. However, the company faces challenges with profitability and sustaining positive operating cash flow. Continued focus on improving operational efficiency and profitability will be crucial for long-term success.

Income Statement

ClearPoint Neuro has shown a consistent increase in revenue over the years, with a notable revenue growth rate of 31% from 2023 to 2024. However, the company continues to operate at a loss with a negative net profit margin of -60.3% in 2024. The gross profit margin remains strong at 60.9%, indicating efficient cost management relative to revenue. The EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.

Balance Sheet

The company's balance sheet shows improvement in stockholders' equity, which increased to $25.4 million in 2024 from $21.2 million in 2023. The debt-to-equity ratio has improved significantly over the years, standing at 0.14 in 2024, indicating lower leverage risk. The equity ratio is robust at 64.8%, highlighting a strong capital structure. However, the company needs to address its negative net income for better return on equity.

Cash Flow

ClearPoint Neuro's cash flow situation shows a positive trend in free cash flow growth, with free cash flow improving by 37.6% from 2023 to 2024. However, the operating cash flow remains negative, which could impact long-term sustainability. The company has been financing its operations through external funding, as seen in its financing cash flow.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
32.24M	31.39M	23.95M	20.55M	16.30M	12.83M
	Gross Profit
19.73M	19.12M	13.61M	13.53M	11.29M	9.12M
	EBIT
-21.68M	-19.75M	-22.45M	-16.33M	-13.37M	-6.22M
	EBITDA
-20.25M	-17.84M	-20.99M	-15.58M	-12.74M	-4.79M
	Net Income Common Stockholders
-20.79M	-18.91M	-22.09M	-16.54M	-15.32M	-9.11M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
12.39M	20.10M	23.14M	37.49M	54.11M	20.10M
	Total Assets
30.07M	39.19M	42.66M	55.49M	65.58M	29.64M
	Total Debt
3.44M	3.57M	13.94M	11.99M	12.28M	24.24M
	Net Debt
-8.95M	-16.54M	-9.20M	-15.63M	-41.83M	4.14M
	Total Liabilities
10.08M	13.80M	21.49M	18.60M	16.79M	27.26M
	Stockholders Equity
19.99M	25.39M	21.17M	36.89M	48.79M	2.38M
Cash Flow		Free Cash Flow
-11.74M	-9.22M	-14.77M	-17.31M	-12.87M	-8.29M
	Operating Cash Flow
-11.28M	-8.95M	-13.72M	-16.17M	-12.70M	-7.81M
	Investing Cash Flow
-458.00K	-275.00K	8.95M	-10.74M	-168.00K	-482.00K
	Financing Cash Flow
-11.23M	6.19M	296.00K	409.00K	46.88M	22.69M

ClearPoint Neuro Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.93
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLPT, the sentiment is Positive. The current price of 13.93 is above the 20-day moving average (MA) of 12.76, above the 50-day MA of 12.75, and above the 200-day MA of 13.56, indicating a bullish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 59.22 is Neutral, neither overbought nor oversold. The STOCH value of 80.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLPT.

ClearPoint Neuro Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLPT	61 Neutral	$362.64M	―	-76.21%	―	23.22%	9.54%
TCMD	60 Neutral	$235.04M	15.16	8.12%	―	5.96%	-43.83%
VREX	56 Neutral	$347.35M	―	-7.46%	―	-3.31%	-199.23%
Sector *	54 Neutral	$5.24B	3.27	-45.39%	2.80%	16.77%	-0.07%
NPCE	50 Neutral	$435.56M	―	-128.49%	―	22.05%	29.86%
NNOX	46 Neutral	$327.10M	―	-30.11%	―	15.32%	15.73%
PACB	41 Neutral	$300.08M	―	-177.29%	―	-23.99%	-100.40%

ClearPoint Neuro Corporate Events

ClearPoint Neuro Approves Key Proposals at Annual Meeting

On May 21, 2025, ClearPoint Neuro, Inc. held its annual stockholders meeting where several key proposals were approved. These included the election of eight directors, the ratification of Cherry Bekaert LLP as the independent public accounting firm, and the approval of executive compensation and its voting frequency. Additionally, the stockholders approved the Amended and Restated 2021 Employee Stock Purchase Plan and the Sixth Amended and Restated 2013 Incentive Compensation Plan. These approvals are expected to impact the company’s governance and compensation strategies moving forward.

The most recent analyst rating on (CLPT) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.

ClearPoint Neuro Updates Director Compensation Plan

ClearPoint Neuro, Inc. has revised its Non-Employee Director Compensation Plan to attract and retain qualified board members by offering appropriate compensation. The updated plan, last revised on May 22, 2023, reflects the company’s commitment to strong corporate governance practices.

The most recent analyst rating on (CLPT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.

ClearPoint Neuro Reports Record Q1 2025 Revenue Growth

On May 13, 2025, ClearPoint Neuro reported its financial results for the first quarter of 2025, highlighting a record revenue of $8.5 million, marking an 11% increase from the previous year. The company experienced significant growth in its single-use navigation and therapy products, with a 70% increase in neurosurgery navigation and therapy revenue and a 104% rise in consumable product revenue. The FDA clearance of ClearPoint 3.0 Software contributed to this growth, enhancing operating room navigation and laser therapy capabilities. Despite capital market volatility, ClearPoint secured a long-term credit facility and equity investment, strengthening its financial position to achieve strategic objectives.

The most recent analyst rating on (CLPT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.

ClearPoint Neuro Secures $110 Million Investment Deal

On May 12, 2025, ClearPoint Neuro announced a significant financial arrangement with Oberland Capital, securing up to $110 million in investment. This includes a $105 million note financing and a $3.5 million stock purchase, aimed at supporting the company’s growth in cell and gene therapy markets. The proceeds will be used for general corporate purposes, including capital expenditures and working capital. This partnership is expected to bolster ClearPoint Neuro’s ability to meet the demands of its pharmaceutical partners and expand its product offerings, thereby enhancing its market position in the medical technology industry.

The most recent analyst rating on (CLPT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.